China Pharma Holdings (CPHI) Receivables - Net (2010 - 2026)

China Pharma Holdings has reported Receivables - Net for 17 years, with the latest figure at $205696.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 37.46% year-over-year to $205696.0; the trailing twelve-month figure through Mar 2026 stood at $205696.0 (down 37.46% YoY), and the FY2025 full-year result was $241412.0, down 98.25% from the prior year.
• Receivables - Net for Q1 2026 stood at $205696.0, down from $241412.0 in the prior quarter.
• The five-year high for Receivables - Net was $14.1 million in Q1 2024, with the low at $205696.0 in Q1 2026.
• Historically, Receivables - Net has averaged $1.9 million across 5 years, with a median of $333371.0 in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Net surged 2639.49% — and 2025, when it tumbled 98.25%.
• China Pharma Holdings' Receivables - Net stood at $421531.0 in 2022, then grew by 19.67% to $504448.0 in 2023, then surged by 2639.49% to $13.8 million in 2024, then plunged by 98.25% to $241412.0 in 2025, then slipped by 14.79% to $205696.0 in 2026.
• The last three Receivables - Net figures came in at $205696.0 (Q1 2026), $241412.0 (Q4 2025), and $224638.0 (Q3 2025), per Business Quant data.